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ABSTRACT
Transient transfection allows for fast production of
recombinant proteins. However, the current bottle-
necks in transient transfection are low titers and low
specific productivity compared to stable cell lines.
Here, we report an improved transient transfec-
tion protocol that yields titers exceeding 1g/l in
HEK293E cells. This was achieved by combining a
new highly efficient polyethyleneimine (PEI)-based
transfection protocol, optimized gene expression
vectors, use of cell cycle regulators p18 and p21,
acidic Fibroblast Growth Factor, exposure of cells
to valproic acid and consequently the maintenance
of cells at high cell densities (4 million cells/ml). This
protocol was reproducibly scaled-up to a working
volume of 2l, thus delivering `1g of purified protein
just 2 weeks after transfection. This is the fastest
approach to gram quantities of protein ever
reported from cultivated mammalian cells and
could initiate, upon further scale-up, a paradigm
shift in industrial production of such proteins for
any application in biotechnology.
INTRODUCTION
Recombinant proteins are of great commercial and scien-
tiﬁc interest. Yet, most current production methods in
mammalian cells involve the time- and labor-consuming
step of creating stable cell lines (1). In some instances,
it might not even be feasible to generate a stable
cell line expressing a particular protein of interest.
Here, production methods based on transient gene expres-
sion can oﬀer a solution (2–6).
However, the major bottlenecks in transient transfec-
tion are low titers and low speciﬁc productivity compared
to stable cell lines (7,8): whereas transient transfection
yields titers in the range of 20–40mg/l with a speciﬁc pro-
ductivity of 1–4pg/cell/day, stable cell lines reach 1–2g/l
with a speciﬁc productivity of 20–50pg/cell/day (1).
Here, we report an optimized transient protein produc-
tion method that yields titers exceeding 1g/l in HEK293E
cells. The HEK293E cell line used is a suspension adapted
human embryonic kidney-293-based cell line stably expres-
sing the Epstein–Barr virus nuclear antigen (EBNA1) (6,9).
Titers were obtained by combining rational vector
designwithmulti-pathwaymodulationbasedonpreviously
performed systematic optimizations of each transfection
parameter (10–12) in HEK293E cells. In short, cells were
transfected at high cell densities (20 million cells/ml) with
25-kd linear polyethyleneimine (10,13,14) with a total of
ﬁve HEK 293-optimized expression vectors encoding IgG
heavy chain, IgG light chain, the cell cycle regulators p18
and p21 and the growth factor acidic Fibroblast Growth
Factor (aFGF). Upon adjustment of cell density to 4 mil-
lion cells/ml, cells were subsequently exposed to valproic
acid for 10–14 days.
Titers obtained in small-scale experiments were repro-
duced in orbitally shaken bioreactors (15) with a working
volume of 2l obtaining a yield of 860mg/l, thus delivering
41g of puriﬁed protein just 2 weeks after transfection.
This is the fastest approach to gram quantities of protein
ever reported from cultivated mammalian cells and could
initiate, upon further scale-up, a paradigm shift in indus-
trial production of such proteins for any application in
biotechnology.
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Vector construction
pEAK8-LH39 and pEAK8-LH41 carrying the full-length
cDNAs of the anti-Rhesus D light and heavy chain IgG
genes, respectively, were described previously (16). pEAK8
waspurchasedfromEdgeBiosystems(Gaithersburg,MD).
Cloning of pXLG
HEK-RhHC and pXLG
HEK-RhLC, car-
rying the full-length cDNAs of the anti-Rhesus D heavy
andlightchainIgGgenes, respectively,aswellascloningof
pXLG
HEK-p21h (encoding the human cell cycle regulatory
protein p21), pXLG
HEK-p18h (encoding the human cell
cycle regulatory protein p18) and pXLG
HEK-aFGF
(encoding the human acidic Fibroblast Growth Factor)
were achieved as previously described (17).
To summarize: vector pXLG
HEK-p21h was chemically
synthesized (GENEART AG, Regensburg, Germany)
based on sequence information provided (Supplementary
Data). The human cDNAs coding for aFGF
(acidic Fibroblast Growth Factor or Fibroblast Growth
Factor 1) and p18h were purchased from RZPD GmbH
(Berlin, Germany). pXLG
HEK vectors were then cloned
by replacing p21h in pXLG
HEK-p21h with the transgene
of interest, where the transgene of interest was cloned by
PCR. All forward and reverse PCR primers were designed
by using the ﬁrst or last 15bp of the corresponding cDNA
sequences. The forward primers were extended with the
sequence 50-AAAGCGGCCGCC-30, which harbors a
NotI restriction site; the reverse primers were extended
with the sequence 50-TAAGCTTAA-30, which harbors a
HindIII site. PCR was performed using Pfu Polymerase
according to supplier instructions. The fragments were
then cloned after restriction digestion into the pXLG
HEK
vector backbone from pXLG
HEK-p21h, which was opened
via digestion with NotI and HindIII, which removed the
p21h cDNA cassette. The correctness of the cDNA
sequences was then veriﬁed by DNA sequencing.
pXLG
HEK vectors comprise the human CMV promoter,
an artiﬁcial intron followed by an optimized 50-untrans-
lated region with Kozak consensus sequence, two stop
codons, the woodchuck post-regulatory element (WPRE)
as 30-untranslated region (18) as well as the bovine growth
hormone polyadenylation signal. The gene expression cas-
sette is ﬂanked by two inverted terminal repeats. The full
sequence of pXLG
HEK including a vector map can be
found in the Supplementary Data.
Plasmid DNAs were puriﬁed on a Nucleobond AX
anion exchange column (Macherey-Nagel, Dueren,
Germany) according to the manufacturer’s protocol.
Transfection
Expansion of cell culture. Suspension-adapted HEK293E
cells (6) were adapted to suspension growth under serum-
free conditions in Ex-Cell 293 CDM (Cat. No. 14571-
1000M; Lot No. 4L1122; SAFC Biosciences, Lenexa,
Kansas, USA, ‘Ex-Cell’ medium) supplemented with
4mM glutamine. The cells were routinely grown in
square-shaped glass bottles (Schott Glass, Mainz,
Germany) in Ex-Cell medium (15,19). Medium was kept
at levels equal to or less than 1/3 of the bottle volume.
The bottles were ﬁxed to a horizontal Model ES-W orbital
shaker with a rotational diameter of 2.5cm (Ku ¨ hner AG,
Birsfelden, Switzerland) using double-sided adhesive trans-
fer tape (3M Corp, Minneapolis, MN) and agitated at
110 r.p.m. (19). Cells were cultured at a density of 10
6
cells/ml up to 3 10
6 cells/ml. Cell passaging was done
by pelleting the cells and re-suspending them at the appro-
priate density in fresh medium.
Transfection with ‘XLG protocol’. Cells were centrifuged
prior to transfection and resuspended at a cell density of 20
million cells/ml in FreeStyle 293 Expression Medium
(‘FreeStyle’ medium, Invitrogen AG, Basel, Switzerland).
Then DNA was added to a ﬁnal concentration of 50 mg/ml
directly to the cells (with a heavy chain to light chain ratio
of 1:1 w/w), followed by addition of the appropriate
amount of a 1mg/ml solution of 25-kd polyethyleneimine
(PEI; Polysciences, Eppelheim, Germany; pH7) to a ﬁnal
concentration of 100 mg/ml. Three hours after transfection,
cells were diluted with Ex-Cell medium to a cell density of
4 10
6 cells/ml, and valproic acid (VPA, Sigma-Aldrich
Chemie GmbH, Industriestrasse 25, CH-9471 Buchs SG,
Catalog NumberP4543)wasaddedtoaﬁnalconcentration
of 3.8mmol/l. The cells were then propagated for
10–14 days under agitation. The ratio of plasmids used
under our optimal production conditions was as follows:
37.5% pXLG
HEK-RhHC, 37.5% pXLG
HEK-LC,
10% pXLG
HEK-p18h, 10% pXLG
HEK-p21h, 5%
pXLG
HEK-aFGF.
All small-scale transfections were made in triplicates
with 10ml ﬁnal volume after dilution in the tube spin
system [TPP AG, Trasadingen, Switzerland; (20)] under
orbital shaking in a Kuhner ISF4-X orbital shaker at
180 r.p.m. in a 5% CO2 atmosphere—unless speciﬁed
otherwise. For the large-scale experiment, cells were culti-
vated in a 5-l Schott glass round bottle in a Kuhner ES-W
orbital shaker at 110 r.p.m. in a 5% CO2 atmosphere.
Transfection with ‘standard protocol’. Prior to transfec-
tion, cells were pelleted, washed once with Phosphate
Buﬀered Saline (PBS), and resuspended at a density of
2 10
6 cells/ml in RPMI 1640 with 25mM Hepes
(pH 7.1) and 4mM L-glutamine (Cat. No. BE12-115Q,
Lot No. 2MB0221; BioWhittaker Europe/Cambrex,
Verviers, Belgium) and 1% Pluronic F68 (‘RPMI F68’).
The transfection cocktail was prepared as follows (quanti-
ties arepermilliliter ofresuspended cells):7.5mlofa1mg/ml
solution of 25-kd polyethyleneimine (PEI; Polysciences,
Eppelheim, Germany; pH7) was added to 42.5mlo f
150mM NaCl (pH7). Separately, 2.5mg of DNA was dis-
solved in 150mM NaCl (pH7) to a ﬁnal volume of 50ml.
Then, the DNA was added to the PEI solution and resus-
pended by pipetting up and down. The complex was incu-
batedforabout8minatroomtemperature,andthenadded
to the cells. Four hours after transfection, an equal volume
of Ex-Cell medium was added (i.e. 1ml of Ex-Cell medium
for each milliliter of RPMI medium.).
Protein analysis
The IgG concentration in the culture medium was deter-
mined by sandwich ELISA as previously described (9).
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(Biosource, Dielsdorf, Switzerland) was used for coating
the ELISA-plates, and the synthesized IgG1 was detected
with AP-conjugated goat anti-human gamma chain IgG
(Biosource, Dielsdorf, Switzerland). NPP was used as
a substrate for the alkaline phosphatase. Absorption
was measured at 405nm against 490nm using a micro-
plate reader (SPECTRAmax
TM340; Molecular Devices,
Palo Alto, CA, USA).
In order to detect the Fc-tagged fusion proteins, goat
anti-human IgG (Fc Fragment speciﬁc; Jackson
ImmunoResearch Laboratories Inc, West Grove, PA,
USA; Code Number 109-006-098; Lot No. 72349) was
used for coating the ELISA-plates. As a detection anti-
body, we used AP-conjugated goat anti-human gamma
chain IgG (Biosource, Dielsdorf, Switzerland). NPP was
used as a substrate for the alkaline phosphatase.
Absorption was measured at 405nm against 490nm using
a microplate reader (SPECTRAmax
TM340; Molecular
Devices, Palo Alto, CA, USA). Antibody was also puriﬁed
using Streamline Protein A beads according to manufac-
turer’s instructions (GE Healthcare, Uppsala, Sweden) and
quantiﬁed spectrophotometrically.
Cell mass andviability
Cell mass and viability were determined as previously
described. In short, the voluPAC system (Sartorius AG,
Go ¨ ttingen, Germany) was used to determine packed cell
volume (PCV) which was correlated to cell density as prev-
iously described (21). In order to transform Packaged Cell
Volume (PCV) into million cells/ml, we used a factor of
0.55 for HEK293E; for example, a PCV of 1.1 (i.e. 1.1%
packaged cell volume) corresponds to 2 million HEK293E
cells/ml.
Analysis ofvariance (ANOVA)
Design of experiments strategy was used in order to deter-
mine statistically signiﬁcant independent and synergistic
eﬀects of the components (factors) of the XLG transfec-
tion protocol. The factors considered were cell density,
p21, p18, aFGF and VPA. Full factorial experimental
design (2
5=32 experiments) was selected over other
experimental designs as this allowed ﬁtting of the data
to a linear model with all possible interaction terms for
each of the factors. The coeﬃcients of this model provide
us with the magnitude and the statistical signiﬁcance of
the eﬀects due to each of the factors, alone and in combi-
nation. A two-level design was chosen where each factor
could have a high or low value (+1 or  1), where +1
indicates presence and  1 indicates absence of that factor,
except in the case of cell density where+1 indicates a
PCV of 2.2 and  1 indicates a cell density of 1.1. The
set of 32 experiments was performed thrice on three sepa-
rate days in order to remove any biases due to condition of
cells or other human factors on the day of transfection.
Samples were collected 12 days after transfection and
ELISA was performed as described above. The results
were normalized with respect to one of the 32 experiments
(same experiment in all three cases) as an internal control
in order to remove any biases due to ELISA variations.
Upon collection of data from all three experimental sets,
the coeﬃcients of the parametric model were calculated
using a least squares ﬁt. Analysis of Variance (ANOVA)
was performed on these coeﬃcients in order to identify
statistically signiﬁcant eﬀects by choosing only those coef-
ﬁcients whose P-values were <5%.
RESULTS
Rationalvector design tailored to HEK293E cells is
essential forhigh-yield recombinant protein production
In the ﬁrst set of experiments, we used a rational vector
design approach to speciﬁcally tailor vectors for high-
yield recombinant protein production in HEK293E cells.
For that purpose, we compared diﬀerent high-yield enhan-
cer/promoters (human eIF1a, mouse CMV, human CMV)
in the context of HEK293E cells. In order to make a valid
comparison, we cloned each enhancer/promoter into the
same vector backbone of an IgG heavy chain and IgG
light chain expression vector, respectively. We then trans-
fected HEK293E cells with the corresponding constructs
using a previously published (standard) protocol. As
depicted in Figure 1, the human CMV enhancer/promoter
performs the best in HEK293E cells. We then further opti-
mized the vector backbone by introducing an intron
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Figure 1. Rational vector design tailored to HEK293E cells is essential
for high-yield recombinant protein production. Comparison of diﬀerent
high-yield enhancer/promoters (human eIF1a, mouse CMV, human
CMV) and regulatory elements (intron, WPRE). All elements were
cloned into the same vector backbone of an IgG heavy chain and
IgG light chain expression vector, respectively. We then transfected
HEK293E cells with the corresponding constructs using the standard
protocol and measured IgG yields via ELISA at day 5.
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(WPRE) (17), resulting in the pXLG
HEK vector backbone,
which further increased recombinant titers by a factor of
 10 compared to the use of the eIF1a promoter alone. We
also tested diﬀerent polyadenylation signals [from SV40,
bovine growth hormone as well as an artiﬁcial polyadenyl-
ation signal (17)], but did not detect a statistically signiﬁ-
cant diﬀerence (data not shown).
Multi-pathway modulationof HEK293E cells in
combination withstep-wise optimization of astandard
transfection protocolincreases recombinant antibody titers
byafactor of  27 from 40mg/l to1.1g/l
In the second set of experiments, we performed a multi-
pathway modulation of HEK293E cells in combination
with step-wise optimization of a standard transfection
protocol to increase recombinant antibody titers by a
factor of 27 from 40mg/l to 1.1g/l. For that purpose,
we compared ﬁve critical parameters for high-yield tran-
sient gene expression in HEK293E cells: cell density (from
1 million cells/ml to 8 million cells/ml), expression of
human cell cycle regulatory proteins (p15, p16, p18, p19,
p21, p27, p57), expression of human growth factors
[IGF-1; transferrin; TGF-b; FRS2; FRS3; acidic
Fibroblast Growth Factor (aFGF); FGF7, 9, 12, 13, 14,
18, 19, 20, 21, 23] and the addition of histone deacetylase
inhibitors (valproic acid, sodium butyrate, MS-275, tri-
chostatin) and inhibitors of DNA methyltransferases [aza-
cytidine (azaC), RG-108, procainamide, hydralazine].
Based on our initial screen of the individual components
(10–12) (data not shown), we have identiﬁed the following
parameters as crucial: cell density (4 million cells/ml),
expression of p18h and p21h (in terms of cell cycle regula-
tory proteins), expression of aFGF (in terms of growth
factors) and addition of VPA (in terms of histone deacety-
lase and DNA methyltransferase inhibitors). We then
directly compared this optimized protocol (henceforth
referred to as the XLG protocol) with a previous standard
protocol (see ‘Materials and Methods’ section). In short,
for the XLG protocol, we transfected HEK293E cells at a
density of 20 million cells/ml in FreeStyle medium by
directly adding plasmid DNA to a ﬁnal concentration of
50mg/ml and PEI to a ﬁnal concentration of 100mg/ml.
Three hours after transfection, cells were diluted to 4 mil-
lioncells/mlwithEx-Cellmedium,andVPAwasaddedtoa
ﬁnal concentration of 3.8mmol/l. The following plasmids
were used (w/w ratio): 37.5% pXLG
HEK-RhHC, 37.5%
pXLG
HEK-RhLC, 10% pXLG
HEK-p18h, 10%
pXLG
HEK-p21h, 5% pXLG
HEK-aFGF.
For the standard protocol, cells were transfected at
a density of 2 million cells/ml in RPMI medium with
2.5mg/ml DNA and 7.5mg/ml PEI (ﬁnal concentrations).
Four hours after transfection, the cells were diluted to 1
million cells/ml with Ex-Cell medium. Only two plasmids
were used for the transfection (w/w): 50% pXLG
HEK-
RhHC and 50% pXLG
HEK-RhLC.
As one can see (Figure 2A), the XLG protocol increases
recombinant protein titers by a factor of 27 from 40mg/l to
1.1g/l (which corresponds to an average speciﬁc productiv-
ity, calculated over the entire duration of the culture,
of3.9pgcell
 1day
 1and22.1pgcell
 1day
 1,respectively).
This is most likely driven by improving cell viability
through the addition of p18h, p21h and higher speciﬁc pro-
ductivitythroughtheadditionofaFGF.VPAasachemical
additive exerts wide ranging eﬀects on various aspects of
protein expression, some direct, (transcription, translation,
secretion), and some indirect (eﬀects on cell cycle and cell
division)—similar to those shown for other chemical addi-
tives such as sodium butyrate (22). In order to fully eluci-
date the role of VPA, further analysis would be required
using high-throughput methods such as DNA microarrays.
In summary, our experiments show that VPA signiﬁcantly
impacts both cell viability and speciﬁc productivity (see
also Figure 3B; data not shown). Our results also indicate
that cell division decreases recombinant yields—due to loss
of plasmids during cell division, i.e. not all plasmids relo-
cate into the nucleus; once the cells are growth arrested, the
number of plasmids per nucleus stays rather constant (data
not shown). To our knowledge, this is the ﬁrst study to
describe titers based on transient gene expression in the
range of 1g/l, a productivity level, which has previously
been demonstrated only for stable cell lines.
In order to quantify and statistically validate the impact
and interaction of the productivity levers identiﬁed, we
performed an Analysis of Variance (ANOVA) based on
the XLG protocol varying each of these ﬁve factors using
factorial design (see ‘Materials and Methods’ section). The
data set obtained from 3 32 experiments (32 experiments
on three diﬀerent days) was ﬁtted to a linear model
(e.g.a0+a1x1+a2x2+a12x1x2) with all possible interac-
tion terms using a least squares ﬁt, thus giving us 32 coeﬃ-
cients indicative of the eﬀects of each of the factors,
individually or in combination with other factors. An
ANOVA was performed for these 32 coeﬃcients allowing
us to calculate the P-values, i.e. the probability that the
value of the coeﬃcient was obtained due to random
errors (background noise) in the experimentation, and
these values were plotted versus the magnitude of the coef-
ﬁcient (Figure 2B). All the factors with a P-value <5% are
considered statistically signiﬁcant. In summary, VPA had
the strongest positive impact on transient gene expression
(an independent eﬀect of 4.51 with signiﬁcant interactions,
Figure 2B), followed by co-expression with aFGF (an inde-
pendent eﬀect of 0.81 with signiﬁcant interactions,
Figure 2B). In order to compare the eﬀects of the various
co-expressed genes, we re-calculated the coeﬃcients assum-
ing VPA was always used and cell density was always
4 million cells/ml, as these were the conditions which gave
us the highest yield (Figure 2C). Out of the genes used,
presence of aFGF and p21h had the strongest positive
impact. p18h only showed a signiﬁcant impact in combina-
tion with aFGF whereas p21h in the same setting had a
slightly negative impact (Figure 2C), and therefore the
two eﬀects cancelled each other at a given cell density.
Our protocolisscalable tothe 2-l scale and applicable
to other transgenes and vector backbones
In the third set of experiments, we demonstrated scalabil-
ity of the XLG protocol to the 2-l scale and applicability
to other transgenes and vector backbones. In a ﬁrst step,
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(Figure 3A). For that purpose, we transfected 8 billion
HEK293E cells in 400ml FreeStyle medium according to
the XLG Protocol (as described in ‘Materials and
Methods’ section) with 20mg DNA and 40mg PEI at a
concentration of 1mg/ml each. Three hours after transfec-
tion, we diluted the cells by adding 1.6l Ex-Cell medium.
Titers and cell viability were determined daily over a
10-day period. As depicted in Figure 3A, titers reached
 860mg/l at day 10 after transfection with cell viability
at around 50%. This is roughly in the range of our small-
scale experiments. After Protein A puriﬁcation, we were
able to recover 1.2g of total recombinant antibody, which
corresponds to a recovery rate of  70%, conﬁrming our
ELISA results. In addition, the ﬁnal product dominated in
both the crude supernatant and the Protein A puriﬁed
product as veriﬁed by SDS-PAGE; there were no major
signs of antibody degradation (data not shown).
We then assessed if our protocol is also applicable
to non-IgG proteins and tested it in combination with
Fc-fusion proteins to the soluble receptors TNFR
(Tumor Necrosis Factor receptor), FGFR1, FGFR2,
FGFR3 and FGFR4 (Fibroblast growth factor receptor
1, 2, 3, 4 respectively) in the context of the pXLG
HEK
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Figure 2. Multi-pathway modulation of HEK293E cells in combination with step-wise optimization of a standard transfection protocol increases
recombinant antibody titers by a factor of 27 from 40 to 1.1g/l. (A) Comparison of the standard protocol to the XLG protocol. HEK293E cells were
transfected as described in ‘Materials and Methods’ section. IgG titers were measured every day until cell viability dropped below 50%. (B and C)
Results of ANOVA based on a design of experiments strategy in order to determine statistically signiﬁcant independent and synergistic eﬀects of the
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mental design (2
5=32 experiments) was selected. Transfections were performed in triplicates as described in ‘Materials and Methods’ section. (B)
Summary data of all 32 experiments. (C) Assumes VPA is always used, i.e. the VPA eﬀect is included in the constant.
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40 million cells in 2ml FreeStyle medium according to
the XLG protocol (as described in ‘Materials and
Methods’ section) and diluted afterwards by adding 8ml
of Ex-Cell medium. Titers were determined 14 days after
transfection. Titers of up to 941mg/l were obtained
with signiﬁcant variance between the diﬀerent proteins
(TNFR-Fc 941 92mg/l; FGFR1 341 19mg/l,
FGFR2 766 8mg/l, FGFR3 244 38mg/l, FGFR4
266 4mg/l).These diﬀerences could most likely be due
tosuboptimalfusionoftheFc-parttothesolublereceptors,
suboptimal codon usage in some of these constructs or
lower secretory potential of some of these proteins. It is
also possible that the magnitude of eﬀects of the factors
delineated above and analyzed by ANOVA, might be dif-
ferent for diﬀerent proteins depending on the nature of the
limiting step for the speciﬁc proteins or vector constructs.
Still, the XLG protocol in all instances yielded titers high
enough to produce suﬃcient material for pre-clinical
experiments.
Last, we evaluated how the XLG protocol performs in
the context of vector backbones that performed poorly
with the standard transfection protocol (Table 1). For
that purpose, we chose ﬁve vectors expressing various anti-
bodies in the context of pMyk and pEAK8 vector back-
bones with titers ranging from 0.1 to 35mg/l with the
standard transfection protocol (see ‘Materials and
Methods’ section). With the XLG protocol, titers could
be increased by a factor of 18 to 168—with a more signiﬁ-
cant increase at lower ‘standard’ titers. For example, the
titer for pMyk 301/302 was increased from 0.1mg/l to
21mg/l, which—although still low—would at least enable
the production of suﬃcient material to conduct preclinical
experiments.
We then tested if changing the vector backbone to
pXLG
HEK would further increase titers. For that purpose,
we cloned the cDNA for the heavy and light chains from
pEAK8-LH39 and pEAK8-LH41 into pXLG
HEK, leading
to vectors pXLG
HEK-RhHC and pXLG
HEK-RhLC. As
can be seen in Figure 3B, the addition of the aFGF expres-
sion plasmid to the transfection cocktail did not aﬀect
pEAK8-driven gene expression, but increased expression
from the pXLG
HEK vector backbone by a factor of  1.7.
Altogether, we increased expression from  7mg/l for
pEAK-LH39/41 with a standard transfection protocol to
1053mg/l with the XLG protocol for pXLG
HEK-RhHC/
RhLC, which is a factor of  150.
DISCUSSION
Reported titers from transient transfections of mamma-
lian cells, small scale or large scale, are at minimum 1
log lower than those reported from stably transfected,
optimized cell lines used in manufacturing of recombinant
proteins in bioreactors. Here, we report a method that
brings transient expression titers into the range of those
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Figure 3. The XLG protocol is scalable to the 2-l scale and speciﬁcally
adapted to the pXLG
HEK vector backbone. (A) Results of large-scale
transient transfection experiment with XLG protocol (2-l scale). Eight
billion HEK293E cells were transfected in 400ml FreeStyle medium
according to the XLG Protocol (as described in ‘Materials and
Methods’ section). Titers and cell viability were determined daily over
a 10-day period. (B) Comparison of pEAK8 and pXLG
HEK vector
backbone when used in combination with vectors coding for p18h,
p21h and with and without a FGF.
Table 1. Transient gene expression of ﬁve diﬀerent vectors pairs, each
encoding a diﬀerent recombinant antibody
Vector(s) Titer (mg/l) Fold increase
Standard protocol XLG protocol
pMyk K4/M4 34.8 2.7 636.3 76.4 18.3
pMyk R1/R2 2.4 0.3 42.7 6.9 17.7
pMyk V1/V2 0.3 0.1 17.1 5.8 64.2
pMyk 301/302 0.1 0.02 21.0 1.1 167.9
pEAK LH39/40 7.2 0.6 138.2 9.0 19.2
Titers including standard deviation are shown based on transfection
with the standard protocol and the XLG protocol as well as the
increase achieved by applying the XLG protocol.
e96 Nucleic Acids Research, 2008, Vol. 36, No. 15 PAGE6 OF 7of stable cell lines. In addition the timeline to establish
such a process is short and can be reproduced in a
matter of days, not months (as is the standard for stable
production).
Our method will be useful in many areas of basic and
applied biotechnology research, where large amounts of
diﬀerent proteins will have to be produced in a short
period of time such as proteomics applications or screen-
ing of antibody leads. Due to the speed of establishment of
high level production, once the appropriate conditions
have been assembled, our protocol will enable certain bio-
defense applications, where an antibody or vaccine will
have to be produced in large quantities within weeks.
One could even imagine scenarios in which proteins are
regularly produced under good manufacturing practices
(GMP) conditions by means of transient transfection—
eliminating the time-consuming steps of establishing and
banking stable cell lines and performing process develop-
ment for each individual clone.
Furthermore, instead of purchasing expensive growth
factors, growth factors can be expressed in situ.
Transient gene expression also allows for the introduction
of factors into mammalian cells that are incompatible with
long-term cell survival or biomass expansion (such as p18
or p21) without the need for a tight, inducible gene expres-
sion system: as biomass expansion takes place prior to
transfection, there are no limitations of this kind.
Indeed, one can independently optimize each step of the
manufacturing cycle, from biomass expansion via trans-
fection to protein production.
In summary, our scalable expression system yields titers
of up to 1g/l with recovery of more than 1g of Protein A
puriﬁed antibody at the 2-l scale, performs similarly for
other recombinant proteins and signiﬁcantly increases
titers also in other vector contexts to the extent that pre-
clinicalexperimentsbecomefeasible.Weareoptimisticthat
the XLG protocol will further accelerate the development
of biotechnology drugs and lead to a paradigm shift in
manufacture of recombinant proteins for commercial use.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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